Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105377 · ClinicalTrials.gov registry record · Phase 2
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
A Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 14
- Study locations
NCT01105377 is a Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 47 participants, above the 26-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (81% higher). The trial reports 14 study locations across 9 states.
The verdict
NCT01105377, a Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase II trial is studying how well giving azacitidine together with entinostat works in treating patients with metastatic colorectal cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with entinostat may kill more tumor cells.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG azacitidine
- DRUG entinostat
Study Locations (14)
Minnesota
- Minnesota Oncology Hematology PA-Maplewood - Maplewood
- Mayo Clinic - Rochester
- Metro-Minnesota CCOP - Saint Louis Park
- United Hospital - Saint Paul
- Lakeview Hospital - Stillwater
Pennsylvania
- University of Pittsburgh Cancer Institute - Pittsburgh
- University of Pittsburgh - Pittsburgh
Arizona
- Mayo Clinic in Arizona - Scottsdale
California
- University of Southern California/Norris Cancer Center - Los Angeles
Florida
- Mayo Clinic in Florida - Jacksonville
Maryland
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center - Baltimore
Michigan
- Wayne State University/Karmanos Cancer Institute - Detroit
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105377
The ClinicalTrials.gov registry entry for NCT01105377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 26-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (81% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Recurrent Colon Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01105377 reports 14 study locations spanning 9 distinct geographic areas - top geographies include Minnesota, Pennsylvania, Arizona.
Frequently Asked Questions
What is clinical trial NCT01105377 about?
NCT01105377 is a clinical study titled "Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer". This phase II trial is studying how well giving azacitidine together with entinostat works in treating patients with metastatic colorectal cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping the...
What is the current status of trial NCT01105377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2010-04. Estimated completion is 2014-05.
What conditions does trial NCT01105377 study?
This clinical trial studies the following conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer.
What interventions are being tested in trial NCT01105377?
The interventions under investigation include: laboratory biomarker analysis (OTHER), azacitidine (DRUG), entinostat (DRUG).
Who is sponsoring clinical trial NCT01105377?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01105377 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
COMPLETED · Phase 2
-
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
COMPLETED · Phase 1
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
COMPLETED · Phase 1
-
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.